FDA Inspection 1269229 — Inner Mongolia Glint Pharmaceutical Co., Ltd.
The FDA completed an inspection of Inner Mongolia Glint Pharmaceutical Co., Ltd. on March 27, 2025 in Chifeng. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 27, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Chifeng (China)